Dr. Will Cole Warns Against High Doses of GLP-1 Medications for Metabolic Health
Dr. Will Cole, a functional medicine expert, has raised concerns about the use of GLP-1 medications, commonly prescribed for weight loss, warning that high doses can act like an 'atomic bomb' for metabolic health. He argues that while these medications can reduce food cravings and promote weight loss, they should not be relied upon exclusively. Instead, Cole advocates for a more balanced approach that includes micro-dosing of peptides alongside nutrition, exercise, and other lifestyle interventions.
As the popularity of peptide therapy grows, Cole notes that these compounds are increasingly being explored for their potential benefits in healthy aging, cellular healing, and metabolic health. He explains that peptides play a crucial role in cellular communication and that their effectiveness depends on the context of their use. Cole highlights the alarming statistic that approximately 93% of U.S. adults are metabolically unhealthy, indicating a pressing need for effective solutions.
Cole cautions against the overreliance on GLP-1 medications, suggesting that while they can be beneficial, they should not be viewed as a standalone solution. He stresses the importance of addressing lifestyle factors that contribute to metabolic issues, such as diets high in ultraprocessed foods and the impact of stress and trauma. He questions whether suppressing hunger cues with high doses of GLP-1 medications could lead to unintended consequences, such as disordered eating patterns and a fear of hunger.
"Food noise," or the natural signals of hunger, can be a healthy part of our relationship with food, Cole argues. He believes that a certain level of hunger signaling is essential and that completely shutting down these cues is not the answer. Instead, he suggests that a more moderate approach, including micro-dosing peptides and pairing them with lifestyle changes, could yield better results for metabolic health.
Cole also emphasizes the need for transparency and product purity in the peptide market, advocating for clear labeling to help healthcare professionals and consumers make informed choices. Despite his concerns, he acknowledges the therapeutic potential of GLP-1s, particularly in reducing inflammation and improving gut health, but reiterates the importance of finding the lowest effective dose that works in conjunction with healthy lifestyle practices.
In summary, Cole's insights highlight the need for a nuanced approach to metabolic health that balances the use of medications with sustainable lifestyle changes, addressing the root causes of metabolic issues rather than relying solely on pharmaceutical solutions.




